Context Therapeutics Inc. financial data

Symbol
CNTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
2001 Market Street, Suite 3915 Unit #15, Philadelphia, PA
State of incorporation
DE
Fiscal year end
December 31
Former names
Context Therapeutics LLC (to 5/3/2021)
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.17K % +19.7%
Debt-to-equity 9.3 % -17.8%
Return On Equity -53.1 % +11%
Return On Assets -48.6 % +9.33%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 75M shares +370%
Common Stock, Shares, Outstanding 75M shares +370%
Entity Public Float 23.8M USD -25.2%
Common Stock, Value, Issued 75K USD +370%
Weighted Average Number of Shares Outstanding, Basic 55M shares +244%
Weighted Average Number of Shares Outstanding, Diluted 55M shares +244%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 6.88M USD -10.3%
Operating Income (Loss) -20M USD -0.69%
Nonoperating Income (Expense) -48.8K USD -373%
Net Income (Loss) Attributable to Parent -18.6M USD +0.88%
Earnings Per Share, Basic -1.06 USD/shares +9.4%
Earnings Per Share, Diluted -1.06 USD/shares +9.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 102M USD +304%
Assets, Current 103M USD +271%
Property, Plant and Equipment, Net 10.4K USD -51%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 103M USD +270%
Accounts Payable, Current 612K USD -48.6%
Employee-related Liabilities, Current 441K USD +3.23%
Accrued Liabilities, Current 993K USD -61.2%
Liabilities, Current 1.6M USD -57.3%
Operating Lease, Liability, Noncurrent 7.97K USD
Liabilities 1.6M USD -57.3%
Retained Earnings (Accumulated Deficit) -74M USD -33.5%
Stockholders' Equity Attributable to Parent 101M USD +321%
Liabilities and Equity 103M USD +270%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.36M USD +23.9%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 75M shares +370%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.36M USD +23.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 102M USD +304%
Deferred Tax Assets, Valuation Allowance 16.6M USD +80.7%
Deferred Tax Assets, Gross 16.8M USD +77.9%
Operating Lease, Liability 0 USD -100%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Operating Lease, Liability, Current 0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 7.75M USD +32.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 175M USD +120%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.57K USD -19.6%
Share-based Payment Arrangement, Expense 908K USD -16.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%